Chimerix, Inc. (NASDAQ:CMRX) Files An 8-K Regulation FD Disclosure
Item7.01
Regulation FD Disclosure. |
Attached hereto as Exhibit 99.1 and incorporated herein by
reference is a corporate update presentation to be utilized by
Chimerix, Inc. at the 35th Annual J.P. Morgan Healthcare
Conference in San Francisco, California.
The information in this Item 7.01 and the attached Exhibit 99.1
is being furnished and shall not be deemed filed for the purposes
of Section 18 of the Securities and Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section.
The information in this Item 7.01 and the attached Exhibit 99.1
shall not be incorporated by reference into any registration
statement or other document to the Securities Act of 1933, as
amended.
Forward-Looking Statements
Statements contained in, or incorporated by reference into, this
Current Report on Form 8-K regarding matters that are not
historical facts are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks are described
more fully in our filings with the Securities and Exchange
Commission, including without limitation our most recent
Quarterly Report on Form 10-Q and other documents subsequently
filed with or furnished to the Securities and Exchange
Commission. All forward-looking statements contained in this
Current Report on Form 8-K speak only as of the date on which
they were made. We undertake no obligation to update such
statements to reflect events that occur or circumstances that
exist after the date on which they were made.
Item9.01 | Financial Statements and Exhibits. |
(d) | Exhibits |
Exhibit No. | Description | |
99.1 | Corporate update presentation of Chimerix, Inc. |
About Chimerix, Inc. (NASDAQ:CMRX)
Chimerix, Inc. (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against over five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir is marketed under the brand name Viread. The Company has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus. Chimerix, Inc. (NASDAQ:CMRX) Recent Trading Information
Chimerix, Inc. (NASDAQ:CMRX) closed its last trading session up +0.20 at 5.23 with 598,213 shares trading hands.